2. 您的位置
3. 首页
4. 会议论文
5. 全RAS基因突变与结直肠癌转移及相关因素的研究

全RAS基因突变与结直肠癌转移及相关因素的研究

来源 :第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 | 被引量 : 0次 | 上传用户：haolei88

【摘 要】

：

目的：分析KRAS,NRAS,BRAF突变情况与结直肠癌患者的临床病理学特征,特别是转移的发生发展进程的关系。方法：序列分析法检测384例结直肠患者的KRAS外显子2,3,4,NRAS外显子2,3,4,BRAF外显子15的突变,并回顾性分析KRAS,NRAS,BRAF突变情况与临床病理学特点间的联系,探讨其与转移方式的关系。

【作 者】

：

赖晓嵘 马冬 

【机 构】

：

广州 广东省人民医院惠福分院胃肠肿瘤内科

【出 处】

：

第十八届全国临床肿瘤学大会暨2015年CSCO学术年会

【发表日期】

：

2015年4期

【关键词】

：

KRAS NRAS BRF 突变 转移 结直肠癌 

下载到本地 , 更方便阅读

下载此文 赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

　　目的：分析KRAS,NRAS,BRAF突变情况与结直肠癌患者的临床病理学特征,特别是转移的发生发展进程的关系。方法：序列分析法检测384例结直肠患者的KRAS外显子2,3,4,NRAS外显子2,3,4,BRAF外显子15的突变,并回顾性分析KRAS,NRAS,BRAF突变情况与临床病理学特点间的联系,探讨其与转移方式的关系。

其他文献

Safety and efficacy of first-line tepotinib (MSC2156119J)in a phase Ⅰb trial in Asian patients with

Objective: The overall prognosis of advanced hepatocellular cancer (HCC) remains poor, with c-Met abnormalities associated with a particularly poor prognosis.The highly selective c-Met inhibitor tepot

会议

hepatocellular cancer

Nomogram and Recursive Partitioning Analysis to Determine the Risk of Cancer-Specific Survival for P

Objective: Whether adjuvant chemoradiotherapy (ACRT) or chemotherapy (ACT) will benefit for stage Ⅱ or Ⅲ upper rectal cancer (URC) after radical surgery remains unclear.

会议

upper rectal canceradjuvant chemoradiotherapyadj

Metabolic tumor burden: a new promising way to reach precise personalised treatment in PDAC

Objective: Pancreatic cancer is currently one of the deadliest solid malignancies and pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer.

会议

PDACpancreatic ductal adenocarcinomaMTB

An open-label, randomized, multicenter study of S-1 vs Gemcitabine in patient with advanced pancreat

Objective: Gemcitabine (GEM) is a standard treatment in patients with advanced pancreatic cancer (PC).S-1 has shown a good efficacy and well safety in Japanese patients from previous studies and has b

会议

Advanced pancreatic cancerS-1GEM

First-line tepotinib (MSC2156119J), an oral c-Met inhibitor, versus sorafenib in Asian patients with

Background: HCC, a poor-prognosis disease for which the only approved drug is sorafenib, has a high unmet need.Factors associated with tumor aggressiveness in advanced HCC include c-Met amplification/

会议

HCC

Continuing single-agent capecitabin as maintenance therapy after induction of XELOX (or FOLFOX) in f

Objective: Colorectal cancer (CRC) is one of the most common malignant tumors.Most of advanced CRC will progress after first-line treatment;therefore, seeking an efficient and low toxic maintaining re

会议

Colorectal cancerMaintenance therapycapecitabine

Circulating tumor cells early predict prognosis of hepatocellular carcinoma treated with transarteri

Objective: To evaluate the potential utility of circulating tumor cells (CTCs) measurements in predicting prognosis of hepatocellular carcinoma (HCC) patients received trans arterial chemoembolization

会议

hepatocellular carcinomacirculating tumor cells

Polymorphism in One-carbon Metabolism Pathway Affects Survival of Gastric Cancer Patients:Large and

Objective: Although it has been shown that polymorphisms in one-carbon metabolism (OCM) pathway are associated with gastric cancer (GC), their interactions and contributions for patients survival are

会议

one-carbon metabolism (OCM)single nucleotide pol

Nomograms based clinical parameters predicting early response for locally advanced rectal cancer wit

Objective: To avoid the damage of radiotherapy for rectal cancer patients, we have designed a phase Ⅱ study comparing Neoadjuvant mFOLFOX6 chemotherapy with or without radiation in locally advanced re

会议

NomogramNeoadjuvant chemotherapyRectal cancer

Clinical outcomes following neoadjuvant nab-paclitaxel and cisplatin chemotherapy for locally advanc

目的： The combination of nab-paclitaxel and cisplatin as preoperative treatment for esophageal squamous cell carcinoma (ESCC) has not been investigated.

会议

nab paclitaxelneoadjuvant chemotherapyesophageal